# Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer

> **NCT02726399** · PHASE2 · TERMINATED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Gastric Cancer
- Gastroesophageal Junction Cancer

## Interventions

- **DRUG:** Ramucirumab
- **DRUG:** Trastuzumab
- **DRUG:** Capecitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02726399
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03-18
- **Primary completion:** 2019-02-26
- **Final completion:** 2019-02-26
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Low accrual rate
- **Last updated:** 2020-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02726399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02726399, "Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02726399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*